

Financial news for VIVO dated on 2020-06-10: Cannabis Stock Gainers And Losers From June 10, 2020

Financial news for VIVO dated on 2020-05-30: Cannabis Stock Gainers And Losers From May 29, 2020

Financial news for VIVO dated on 2020-05-26: Meridian Bioscience Announces It Will Supply Reagents For Manufacturing Of Tens Of Millions Of COVID-19 Antibody Tests Per Month

Financial news for VIVO dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for VIVO dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for VIVO dated on 2020-05-09: Cannabis Stock Gainers And Losers From May 8, 2020

Financial news for VIVO dated on 2020-05-08: Stocks That Hit 52-Week Highs On Friday

Financial news for VIVO dated on 2020-05-08: Meridian Bioscience shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for VIVO dated on 2020-05-08: Recap: Meridian Bioscience Q2 Earnings

Financial news for VIVO dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for VIVO dated on 2020-05-08: Meridian Raises FY20 Guidance: Adj. EPS \$0.70-\$0.75, Sales \$230M-\$236M

Financial news for VIVO dated on 2020-05-08: Meridian Bioscience Q2 EPS \$0.230 Beats \$0.080 Estimate, Sales \$57.300M Beat \$49.260M Estimate

Financial news for VIVO dated on 2020-05-07: Cannabis Stock Gainers And Losers From May 7, 2020

Financial news for VIVO dated on 2020-05-07: Stocks That Hit 52-Week Highs On Thursday

Financial news for VIVO dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for VIVO dated on 2020-05-06: Cannabis Stock Gainers And Losers From May 6, 2020

Financial news for VIVO dated on 2020-05-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for VIVO dated on 2020-05-06: Meridian Bioscience Partners With QuantuMDx On Coronavirus COVID-19 Assay

Financial news for VIVO dated on 2020-05-05: ESPANOL * Noticias del Dia: Una Linea de Ropa de 'Narcos', Alice Moon y el SHC, Acciones de Cannabis, MindMed y el LSD, y Mas

Financial news for VIVO dated on 2020-05-05: Cannabis Stock Gainers And Losers From May 5, 2020

Financial news for VIVO dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for VIVO dated on 2020-04-27: Cannabis Stock Gainers And Losers From April 27, 2020

Financial news for VIVO dated on 2020-04-27: Meridian Bioscience Shares Volatile On Spike In Volume Following Co. Press Release Highlighting Launch Of Novel Enzyme Master Mix That Eliminates Need To Use RNA Extraction Kit Related To Coronavirus Testing

Financial news for VIVO dated on 2020-04-14: Cannabis Stock Gainers And Losers From April 14, 2020

Financial news for VIVO dated on 2020-04-02: Meridian Bioscience Sees Q2 Sales \$57M

Financial news for VIVO dated on 2020-03-23: Cannabis Stock Gainers And Losers From March 23, 2020

Financial news for VIVO dated on 2020-03-17: Cannabis Stock Gainers And Losers From March 17, 2020

Financial news for VIVO dated on 2020-03-16: Meridian Bioscience Announces FDA-Clearance For New Curian Analyzer And Curian HpSA Assay

Financial news for VIVO dated on 2020-03-13: Cannabis Stock Gainers And Losers From March 13, 2020

Financial news for VIVO dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for VIVO dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for VIVO dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for VIVO dated on 2020-03-11: Stocks That Hit 52-Week Lows On Wednesday

Financial news for VIVO dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for VIVO dated on 2020-03-10: Cannabis Stock Gainers And Losers From March, 10. 2020

Financial news for VIVO dated on 2020-02-28: 50 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for VIVO dated on 2020-02-27: Cannabis Stock Gainers And Losers From Feb. 27, 2020

Financial news for VIVO dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for VIVO dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for VIVO dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for VIVO dated on 2020-02-25: Cannabis Stock Gainers And Losers From Feb. 24, 2020

Financial news for VIVO dated on 2020-02-21: Cannabis Stock Gainers And Losers From Feb. 20, 2020

Financial news for VIVO dated on 2020-02-19: Cannabis Stock Gainers And Losers From Feb. 19, 2020

Financial news for VIVO dated on 2020-02-19: Meridian Bioscience Signs Definitive Agreement To Acquire Exalenz Bioscience For \$49M

Financial news for VIVO dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for VIVO dated on 2020-02-10: Stocks That Hit 52-Week Lows On Monday

Financial news for VIVO dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for VIVO dated on 2020-02-07: Meridian Bioscience Q1 Adj. EPS \$0.1 Beats \$0.07 Estimate, Sales \$47.4M Miss \$48.9M Estimate

Financial news for VIVO dated on 2020-02-07: Earnings Scheduled For February 7, 2020

Financial news for VIVO dated on 2020-02-04: 85 Biggest Movers From Yesterday

Financial news for VIVO dated on 2020-01-29: 70 Biggest Movers From Yesterday

Financial news for VIVO dated on 2020-01-28: 13 Diagnostics & Research Stocks Moving In Tuesday's Session

Financial news for VIVO dated on 2020-01-28: 46 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VIVO dated on 2020-01-28: 71 Biggest Movers From Yesterday

Financial news for VIVO dated on 2020-01-27: 13 Diagnostics & Research Stocks Moving In Monday's Session

Financial news for VIVO dated on 2020-01-27: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for VIVO dated on 2020-01-27: Meridian Bioscience Announces Lyo-Ready 1-Step RT-qPCR Mix Is Used In Development Of Molecular Diagnostics For New Coronavirus Outbreak

Financial news for VIVO dated on 2019-11-08: Stocks That Hit 52-Week Lows On Friday

Financial news for VIVO dated on 2019-11-08: 94 Biggest Movers From Yesterday

Financial news for VIVO dated on 2019-11-07: 75 Stocks Moving In Thursday's Mid-Day Session

Financial news for VIVO dated on 2019-11-07: Meridian Bioscience Sees FY20 Adj. EPS \$0.28-\$0.34 May Not Compare To \$0.51 Est.

Financial news for VIVO dated on 2019-11-07: Meridian Bioscience Earlier Reported Q4 EPS \$0.13 Beats \$0.09 Estimate, Sales \$50.846M Beat \$50.59M Estimate

Financial news for VIVO dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for VIVO dated on 2019-11-06: Meridian Submits Curian Analyzer And Curian HpSA Assay To The FDA

Financial news for VIVO dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for VIVO dated on 2019-10-10: Stocks That Hit 52-Week Lows On Thursday

Financial news for VIVO dated on 2019-08-28: Stocks That Hit 52-Week Lows On Wednesday

Financial news for VIVO dated on 2019-08-26: Stocks That Hit 52-Week Lows On Monday

Financial news for VIVO dated on 2019-08-23: Stocks That Hit 52-Week Lows On Friday

Financial news for VIVO dated on 2019-08-22: Stocks That Hit 52-Week Lows On Thursday

Financial news for VIVO dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for VIVO dated on 2019-08-21: The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform

Financial news for VIVO dated on 2019-08-16: The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contempo Resubmission

Financial news for VIVO dated on 2019-08-15: The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

Financial news for VIVO dated on 2019-08-14: The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Financial news for VIVO dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for VIVO dated on 2019-08-07: Stocks That Fell Through 52-Week Lows Wednesday

Financial news for VIVO dated on 2019-07-30: Meridian Bioscience Sees FY19 Adj. EPS \$0.63-\$0.65 vs \$0.56 Est.

Financial news for VIVO dated on 2019-07-30: Meridian Bioscience Q3 EPS \$0.16 Beats \$0.09 Estimate, Sales \$48.44M Miss \$49.81M Estimate

Financial news for VIVO dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for VIVO dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for VIVO dated on 2019-05-01: UPDATE: Canaccord Maintains Sell On Meridian Bioscience, Lowers Target To \$9 As Firm Believes 'the turnaround is not near-term and, if one is possible, it is likely at least 2-3 years away'

Financial news for VIVO dated on 2019-05-01: Canaccord Genuity Maintains Sell on Meridian Bioscience Inc. - Common Stock, Lowers Price Target to \$9

Financial news for VIVO dated on 2019-05-01: 10 Biggest Price Target Changes For Wednesday

Financial news for VIVO dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for VIVO dated on 2019-05-01: Piper Jaffray Upgrades Meridian Bioscience Inc. - Common Stock to Neutral, Lowers Price Target to \$11

Financial news for VIVO dated on 2019-05-01: 68 Biggest Movers From Yesterday

Financial news for VIVO dated on 2019-04-30: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VIVO dated on 2019-04-30: Meridian Bioscience Earlier Reported Q2 Adj. EPS \$0.19 Beats \$0.16 Estimate, Sales \$50.248M Miss \$51.74M Estimate; Suspended Qtr. Dividend

Financial news for VIVO dated on 2019-04-30: Meridian Bioscience To Acquire Business Of GenePOC; Meridian Will Make \$50M Cash Payment At Closing With Future Payments Totalling \$70M Contingent Upon Achievement Of Milestones

Financial news for VIVO dated on 2019-04-30: Meridian Bioscience 8-K Shows Purchase Of Most Assets Of GenePoc Canada To Co. For Up To \$120M

Financial news for VIVO dated on 2019-04-30: The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

Financial news for VIVO dated on 2019-04-18: Meridian Bioscience Reports Launch Of New Inhibitor Tolerant qPCR Reagent To Significantly Simplify Molecular Diagnostic Workflows From Crude Samples

Financial news for VIVO dated on 2019-04-18: The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

Financial news for VIVO dated on 2019-04-17: The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO

Financial news for VIVO dated on 2019-04-04: The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Drovers, Silk Road, NGM Biopharma To Debut

Financial news for VIVO dated on 2019-04-03: Meridian Bioscience shares are trading lower after Canaccord Genuity downgraded the stock from Hold to Sell.

Financial news for VIVO dated on 2019-04-03: Benzinga's Top Upgrades, Downgrades For April 3, 2019

Financial news for VIVO dated on 2019-04-03: Canaccord Genuity Downgrades Meridian Bioscience to Sell

Financial news for VIVO dated on 2019-04-03: 54 Biggest Movers From Yesterday

Financial news for VIVO dated on 2019-04-02: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VIVO dated on 2019-04-02: Meridian Bioscience shares are trading lower after the company provided Q2 sales guidance and FY19 EPS guidance below analyst estimates.

Financial news for VIVO dated on 2019-04-02: Meridian Bioscience Sees Q2 Sales \$50M-\$56.5M vs \$56.37M Est., Sees FY19 Adj. EPS \$0.60-\$0.65 vs \$0.76 Est.

Financial news for VIVO dated on 2019-01-24: The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial

Financial news for VIVO dated on 2019-01-24: Meridian Bioscience Reaffirms FY2019 EPS Guidance of \$0.74-0.76 vs \$0.76 Est

Financial news for VIVO dated on 2019-01-24: Meridian Bioscience Q1 EPS \$0.20 Beats \$0.18 Estimate, Sales \$51.48M Miss \$53.68M Estimate

Financial news for VIVO dated on 2019-01-09: 58 Biggest Movers From Yesterday

Financial news for VIVO dated on 2019-01-08: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VIVO dated on 2019-01-08: The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

Financial news for VIVO dated on 2019-01-07: Meridian Bioscience Sees Q1 Sales \$51.0M-\$51.5M vs \$53.5M Est.

Financial news for VIVO dated on 2018-12-06: Meridian Bioscience Reports FDA Clearance For Its New Neonatal Saliva CMV Test

Financial news for VIVO dated on 2018-11-30: Watching Meridian Biosciences Shares Amid Report FDA Authorized Test To Aid In Detecting A Type Of Herpes Virus In Newborns Called Cytomegalovirus

Financial news for VIVO dated on 2018-11-16: Stocks Trading Ex Dividend For Fri., Nov. 16, 2018

Financial news for VIVO dated on 2018-11-15: Stocks That Will Be Trading Ex Dividend Fri., Nov. 16, 2018

Financial news for VIVO dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for VIVO dated on 2018-11-09: 80 Biggest Movers From Yesterday

Financial news for VIVO dated on 2018-11-08: Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018

Financial news for VIVO dated on 2018-11-08: Meridian Bioscience Sees FY19 EPS \$0.74-\$0.76 vs \$0.77 Est.

Financial news for VIVO dated on 2018-11-08: Meridian Bioscience Inc. Q4 EPS \$0.20 Beats \$0.16 Estimate, Sales \$53.1M Beat \$51.1M Estimate

Financial news for VIVO dated on 2018-10-09: DiaSorin And Meridian Enter Into Strategic Collaboration To Sell Helicobacter Pylori Stool Antigen Test In US And UK

Financial news for VIVO dated on 2018-09-24: Meridian Bioscience Reports Chair John Kraeutler To Retire; David Phillips Name Replacement

Financial news for VIVO dated on 2018-08-09: Stocks Trading Ex Dividend For Thurs., Aug. 9, 2018

Financial news for VIVO dated on 2018-08-08: Stocks Which Will Trade Ex Dividend On Thurs., Aug. 9, 2018

Financial news for VIVO dated on 2018-07-31: Meridian Bioscience Q3 EPS \$0.18 Misses \$0.23 Estimate, Sales \$51.737M Miss \$52.12M Estimate

Financial news for VIVO dated on 2018-07-06: FDA Announces Revised Guidance On Testing Of Donated Blood, Blood Components For Zika

Financial news for VIVO dated on 2018-06-20: Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading

Financial news for VIVO dated on 2018-06-19: Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

Financial news for VIVO dated on 2018-05-30: Meridian Introduces Critical Raw Materials for Nipah Virus Diagnosis, a Key Emerging Disease on the WHO's Priority List

Financial news for VIVO dated on 2018-04-26: Meridian Bioscience Q2 Adj. EPS \$0.27 Beats \$0.21 Est., Sales \$56.5M Beats \$55M Est.

Financial news for VIVO dated on 2018-03-22: Meridian Shares Volatile As FDA Concludes Studies Performed By BD Were Robust & Showed There Was A Significant Chance Of False Results With Magellan's Leadcare Tests; Continues To Recommend That Magellan Lead Tests Not Be Used With Blood Samples From Vein

Financial news for VIVO dated on 2018-03-21: Meridian Bioscience Realignment Organizational Structure, New Structure Consists of two Business Units, Diagnostics

and Life Science, Supported by a Global Corporate Team

Financial news for VIVO dated on 2018-01-25: Meridian Bioscience Reports Q4 EPS \$0.15 vs \$0.15 Est., Sales \$52.28M vs \$49.00M Est.

Financial news for VIVO dated on 2017-11-29: Meridian Bioscience S-3 Filing Shows Registration For \$100M Mixed Securities Shelf Offering

Financial news for VIVO dated on 2017-11-09: Meridian Reaffirms FY18 Adj. EPS \$0.65-\$0.68 vs \$0.68 Est., Sales \$207M-\$212M vs \$204.7M Est.

Financial news for VIVO dated on 2017-11-09: Meridian Bioscience Reports Q4 Adj. EPS \$0.15, Inline, Sales \$49.7M vs \$48M Est.

Financial news for VIVO dated on 2017-10-23: UPDATE: Meridian Says 'Magellan will promptly submit a response to the Warning Letter for the Agency's consideration'

Financial news for VIVO dated on 2017-10-23: Meridian Bioscience Offers Comment Related To FDA Statement Regarding Warning Letter Issued To Magellan Diagnostics

Financial news for VIVO dated on 2017-10-23: Weakness In Meridian Bioscience Is Being Attributed To A FDA Warning Letter Regarding An Inspection Of The Company's Manufacturing

Financial news for VIVO dated on 2017-10-19: Meridian Bioscience Sees fy EPS \$0.66-0.67 vs \$0.67 Est; Sees Sales \$200.50M vs \$198.35M Est

Financial news for VIVO dated on 2017-10-10: Meridian Bioscience, Inc. Names Jack Kenny CEO

Financial news for VIVO dated on 2017-08-25: Meridian Bioscience CEO Kraeutler Buys 7,000 @ Avg Price: \$13.67 -Form4

Financial news for VIVO dated on 2017-08-09: Meridian Bioscience Reports Initiation Of Clinical Trials For New Neonatal Saliva CMV illumigne Test

Financial news for VIVO dated on 2017-07-27: Meridian Biosciences Reports Q3 Adj. EPS \$0.16 vs \$0.17 Est., Sales \$50.14M vs \$49.2M Est.

Financial news for VIVO dated on 2017-07-13: UPDATE: Meridian, Magellan Reiterate Mutual Commitment To Strengthening Magellan's Quality System, Ensuring All Aspects Of System Are In Full Compliance

Financial news for VIVO dated on 2017-07-13: UPDATE: Meridian Says Magellan Will Promptly Submit Responses To Form FDA-483

Financial news for VIVO dated on 2017-07-13: UPDATE: Meridian Highlights Form Represents Investigators' Observations And Is Not A Final Agency Determination

Financial news for VIVO dated on 2017-07-13: Meridian Bioscience Issues Comment Related To FDA Press Statement

Financial news for VIVO dated on 2017-07-13: FDA Says Design Validation For Magellan Diagnostics' Leadcare Test Systems Did Not Ensure Device Conforms To Defined User Needs and Intended Uses, Inspected Facility In North Billerica, Massachusetts

Financial news for VIVO dated on 2017-07-13: CORRECTION: Magellan Health Is Not Related To FDA 483 Doc; Meridian Bioscience Is Owner Of Magellan Diagnostics, The Co. Facility In Question In FDA 483 Doc

Financial news for VIVO dated on 2017-07-13: UPDATE: Observations In FDA 483 Doc On Magellan's North Billerica Facility Include Questions On Design Validation, Inadequate Risk Analysis, Procedures For Corrective, Preventive Action Not Adequately Establish

Financial news for VIVO dated on 2017-07-13: Watching Meridian Bioscience Shares As Traders Circulating FDA 483 Form Including 9 Observations About Magellan's North Billerica Facility; BZ NOTE: Meridian Is Owner Of Magellan

Financial news for VIVO dated on 2017-06-30: UPDATE: Meridian Says '[Co.] and Magellan continue to take these matters very seriously and will continue to work closely and fully with the FDA and CDC to address the concerns identified as quickly as possible.'

Financial news for VIVO dated on 2017-06-30: UPDATE: Meridian Says FDA Concluded Inspection On Magellan's Quality System; Magellan Is Committed To Addressing FDA Investigators' Observations

Financial news for VIVO dated on 2017-06-30: Meridian Bioscience Offers Comments On

Recent FDA Matters Related To Magellan Diagnostics

Financial news for VIVO dated on 2017-06-06: Meridian Bioscience Says They Are Going To Continue Working With The FDA, Doesn't Expect Recall To Cause Any Material Effect To Financial Results

Financial news for VIVO dated on 2017-06-05: FDA Says Meridian Bioscience's Magellan Diagnostics Expands Recall For Leadcare Testing Systems Due To Inaccurate Test Results, Class I Recall

Financial news for VIVO dated on 2017-05-17: Meridian Bioscience Comments on Matter Involving its Subsidiary, Magellan Diagnostics via FDA

Financial news for VIVO dated on 2017-05-17: 15 Biggest Mid-Day Losers For Wednesday

Financial news for VIVO dated on 2017-05-17: Meridian Bioscience Shares Plunge as FDA Issues Warning Certain Lead Tests by Co.'s Magellan Diagnostics Could Provide Inaccurate Results

Financial news for VIVO dated on 2017-05-10: Meridian Bioscience Reports Retirement of CEO John Kraeutler, Engaged Korn Ferry to Conduct Search

Financial news for VIVO dated on 2017-04-27: Meridian Reports Q2 EPS \$0.22, Inline, Sales \$54.125M vs \$51.259M in Same Qtr. Last Year

Financial news for VIVO dated on 2017-02-03: Meridian Bioscience Reports Launch of TruQuick Rapid Tests for Asia Pacific

Financial news for VIVO dated on 2017-01-25: Mid-Afternoon Market Update: Seagate Climbs On Strong Q2 Results; Meridian Bioscience Shares Plummet

Financial news for VIVO dated on 2017-01-25: 15 Biggest Mid-Day Losers For Wednesday

Financial news for VIVO dated on 2017-01-25: Mid-Day Market Update: Dow Surges Over 150 Points; Arctic Cat Shares Rise On Acquisition News

Financial news for VIVO dated on 2017-01-25: Mid-Morning Market Update: Markets Open Higher; Boeing Profit Beats Views

Financial news for VIVO dated on 2017-01-25: Meridian Biosciences Shares to Resume Trade at 8 a.m. EST

Financial news for VIVO dated on 2017-01-25: UPDATE: Meridian Bioscience Lowers FY17 Guidance From \$205-\$210 To \$193-\$199M, EPS From \$0.82-\$0.85 To \$0.64-\$0.69

Financial news for VIVO dated on 2017-01-25: UPDATE: Meridian Reduces Qtr. Dividend From \$0.20 To \$0.125/Share

Financial news for VIVO dated on 2017-01-25: Meridian Bioscience Reports Q1 EPS \$0.15 vs \$0.21 in Same Qtr. Last Year, Sales \$46.809vs \$47.16M Est.

Financial news for VIVO dated on 2017-01-25: Meridian Bioscience Reduces Cash Dividend, Revises Guidance Downward

Financial news for VIVO dated on 2017-01-25: Meridian Bioscience Halted News Pending

Financial news for VIVO dated on 2016-12-20: Meridian Bioscience Signs Exclusive Partnership With MedCaptain Medical Technology To Increase Blood Lead Testing In China

Financial news for VIVO dated on 2016-12-01: MERIDIAN BIOSCIENCE INC: Ellingwood Dwight E (Director) Buys 1,020 @ Avg Price: \$17.12 (Form4)

Financial news for VIVO dated on 2016-11-16: 10 Notable Stocks Trading Ex-Dividend Thursday, November 17

Financial news for VIVO dated on 2016-11-10: Meridian Bioscience Reports Q4 EPS \$0.14 vs. Est. \$0.14, Rev. \$46.9M vs. Est. \$47.7M

Financial news for VIVO dated on 2016-11-07: Meridian Bioscience CEO Kraeutler Buys 5,000 Shares @\$16.13/Share -Form 4

Financial news for VIVO dated on 2016-11-07: Meridian Bioscience VP Baldini Buys 4,900 Shares @\$16.00/Share -Form 4

Financial news for VIVO dated on 2016-10-19: 15 Biggest Mid-Day Losers For Wednesday

Financial news for VIVO dated on 2016-10-19: Stocks Hitting 52-Week Lows

Financial news for VIVO dated on 2016-10-19: Mid-Morning Market Update: Markets Mostly Higher; Morgan Stanley Tops Q3 Estimates

Financial news for VIVO dated on 2016-10-18: Meridian Bioscience Sees FY17 Sales \$205M-\$210M vs \$210.6M Est., EPS \$0.81-\$0.85 vs \$0.91 Est.

Financial news for VIVO dated on 2016-10-18: Meridian Bioscience Sees Q4 Sales ~\$47M vs \$49.3M Est.

Financial news for VIVO dated on 2016-10-18: Meridian Bioscience Sees FY16 Sales ~\$196M vs \$198.5M Est., EPS \$0.75-\$0.76 vs \$0.86 Est.

Financial news for VIVO dated on 2016-08-09: Magellan Diagnostics Receives CFDA Clearance for LeadCare II in China

Financial news for VIVO dated on 2016-08-09: Meridian Bioscience Reports LeadCare II Received CFDA Clearance

Financial news for VIVO dated on 2016-07-29: Hilliard Lyons Downgrades Meridian Bioscience to Hold

Financial news for VIVO dated on 2016-07-28: Meridian Bioscience Sees FY16 Rev. \$195-\$200M vs. Est. \$203M, EPS \$0.86-\$0.90 vs. Est. \$0.88

Financial news for VIVO dated on 2016-07-28: Meridian Bioscience Reports Q3 EPS \$0.21 vs. Est. \$0.22, Rev. \$50.7M vs. Est. \$52.8M

Financial news for VIVO dated on 2016-07-07: Sectors and Stocks To Watch If Hillary Clinton Is Elected

Financial news for VIVO dated on 2016-06-15: Meridian Bioscience, Inc. Receives FDA Clearance for New Molecular Test for the Detection of Mycoplasma pneumoniae

Financial news for VIVO dated on 2016-06-02: Bioline, Meridian Bioscience Subsidiary, Launches New MyTaq Plant-PCR Kit

Financial news for VIVO dated on 2016-04-28: Meridian Bioscience Sees FY16 EPS \$0.86-\$0.90 vs. Est. \$0.89, Rev. \$195-\$200M vs. Est. \$201M

Financial news for VIVO dated on 2016-04-28: Meridian Bioscience Reports Q2 EPS \$0.24 vs. Est. \$0.24, Rev. \$51.3M vs. Est. \$52M

Financial news for VIVO dated on 2016-03-28: UPDATE: Hilliard Lyons Expects VIVO Margins To Take A Hit But Will Be Offset By Additional Revenues

Financial news for VIVO dated on 2016-03-28: Hilliard Lyons Upgrades Meridian Bioscience to Buy, Announces \$22.00 PT

Financial news for VIVO dated on 2016-03-24: Meridian Bioscience Acquires Magellan Biosciences For \$666M

Financial news for VIVO dated on 2016-03-21: Hilliard Lyons Downgrades Meridian Bioscience to Neutral

Financial news for VIVO dated on 2016-01-27: Meridian Bioscience Reaffirms FY16 Outlook: EPS \$0.86-\$0.90 vs \$0.88 Est., Sales \$195M-\$200M vs \$187.9M Est.

Financial news for VIVO dated on 2016-01-27: Meridian Bioscience Reports Q1 EPS \$0.21, Inline, Sales \$47.2M vs \$48.6M Est.

Financial news for VIVO dated on 2016-01-26: Meridian Bioscience, Lean Continuous Improvement Partner For Launch of illumigene Malria

Financial news for VIVO dated on 2015-11-18: Meridian Receives FDA Clearance for New Molecular Whooping Cough Test Claims

Financial news for VIVO dated on 2015-11-12: UPDATE: Meridian Bioscience Announces Investment in Oasis Diagnostics; Terms Not Disclosed

Financial news for VIVO dated on 2015-11-12: Meridian Bioscience Reports Investment in Oasis Diagnostics, No Terms Disclosed

Financial news for VIVO dated on 2015-11-05: Meridian Bioscience Reports Q4 EPS \$0.20 Vs Est \$0.21, Sales \$47.1M Vs Est \$46.64M

Financial news for VIVO dated on 2015-09-16: Top 4 Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2015-09-09: Meridian Bioscience Sees FY16 EPS

\$0.86-\$0.90 vs \$0.93 Est., Sales \$195M-\$200M vs \$203.5M Est.

Financial news for VIVO dated on 2015-09-04: Bioline Launches New EPIK miRNA Panel Assays

Financial news for VIVO dated on 2015-07-20: Meridian Bioscience Given FDA Clearance for New Molecular Amplification Test: illumigene HSV 1&2

Financial news for VIVO dated on 2015-06-23: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Operating Margin

Financial news for VIVO dated on 2015-06-08: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for VIVO dated on 2015-06-04: Meridian Bioscience Reports Launch of Para-Pak SVT

Financial news for VIVO dated on 2015-05-13: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for VIVO dated on 2015-05-05: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA

Financial news for VIVO dated on 2015-05-04: Meridian Bioscience Board Succession Hints At M&A Appetite Change, Canaccord Says

Financial news for VIVO dated on 2015-04-23: Meridian Bioscience Reports Inline Q2 EPS \$0.24, Sales \$51.5M Vs Est \$50.43, Backs Guidance For FY 2015 EPS \$0.85-\$0.91 & Revs \$193M-\$200M

Financial news for VIVO dated on 2015-02-26: Meridian Bioscience Receives CE Marking For 2 New Molecular Amplification Tests

Financial news for VIVO dated on 2015-02-12: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for VIVO dated on 2015-01-23: Craig-Hallum Upgrades Meridian Bioscience to Buy, Raises PT to \$22.00

Financial news for VIVO dated on 2015-01-22: Meridian Bioscience Reports Q1 EPS \$0.19, Inline, Sales \$48M vs \$46M Est.

Financial news for VIVO dated on 2015-01-22: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for VIVO dated on 2015-01-21: Earnings Scheduled For January 21, 2015

Financial news for VIVO dated on 2015-01-02: Benzinga's Top Downgrades

Financial news for VIVO dated on 2015-01-02: Raymond James Downgrades Meridian Bioscience To Underperform

Financial news for VIVO dated on 2015-01-02: Raymond James Downgrades Meridian Bioscience to Underperform

Financial news for VIVO dated on 2014-12-31: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2014-12-18: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for VIVO dated on 2014-12-02: Meridian Life Science Awarded SBIR II by CDC to Develop Rotavirus Vaccine

Financial news for VIVO dated on 2014-12-01: Filing from Meridian Bioscience Shows Registration for Automatic Mixed Securities Shelf Offering

Financial news for VIVO dated on 2014-11-06: Meridian Bioscience Inc. Reports Q4 EPS of \$0.20 vs \$0.22 Est

Financial news for VIVO dated on 2014-10-08: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for VIVO dated on 2014-09-03: Meridian Bioscience Reports Deal with Premier Inc., Will Offer Hospitals Molecular Diagnostic Tests

Financial news for VIVO dated on 2014-09-02: Meridian Bioscience Inc. Sees FY2015 EPS \$0.85-0.91 vs \$0.97 Est; Sees Sales \$193.0M-200.0M vs \$203.80M Est

Financial news for VIVO dated on 2014-07-24: Meridian Bioscience Inc. Reports Q2 EPS of \$0.21 vs \$0.23 Est; Revenue of \$47.20M vs \$47.96M Est

Financial news for VIVO dated on 2014-07-14: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI

Financial news for VIVO dated on 2014-05-28: Meridian Bioscience Announces License Approval for illumigene Mycoplasma, Pertussis from Health Canada

Financial news for VIVO dated on 2014-05-05: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROE

Financial news for VIVO dated on 2014-04-24: Meridian Bioscience Raises Qtrly Dividend 5% to \$0.20/Share

Financial news for VIVO dated on 2014-04-24: Meridian Bioscience Inc. Reports Q2 EPS of \$0.24 vs \$0.27 Est; Revenue of \$50.10M vs \$52.18M Est

Financial news for VIVO dated on 2014-04-23: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for VIVO dated on 2014-04-11: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROA

Financial news for VIVO dated on 2014-03-27: Meridian Bioscience Receives FDA Clearance for Illumigene Pertussis, Will Be Available Within a Month

Financial news for VIVO dated on 2014-03-20: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates

Financial news for VIVO dated on 2014-02-13: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2014-01-30: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Financial news for VIVO dated on 2014-01-23: Top Four Stocks for Income During Period of Low Interest Rates, Bond Yields

Financial news for VIVO dated on 2014-01-22: Meridian Bioscience Raises Dividend to \$0.20

Financial news for VIVO dated on 2014-01-22: Meridian Bioscience Inc. Sees FY2014 EPS \$0.98-1.03 vs \$0.99 Est

Financial news for VIVO dated on 2014-01-22: Meridian Bioscience Inc. Reports Q1 EPS of \$0.18, Inline; Revenue of \$44.80M vs \$47.59M Est

Financial news for VIVO dated on 2014-01-15: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS

Financial news for VIVO dated on 2013-12-30: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA

Financial news for VIVO dated on 2013-12-18: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Financial news for VIVO dated on 2013-12-03: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue

Financial news for VIVO dated on 2013-11-12: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Financial news for VIVO dated on 2013-11-07: Meridian Bioscience Inc. Sees FY2014 EPS \$0.98-1.03 vs \$1.00 Est; Sees Sales \$203.0M-208.0M vs \$205.05M Est

Financial news for VIVO dated on 2013-11-07: Meridian Bioscience Inc. Reports Q4 EPS of \$0.22 vs \$0.23 Est; Revenue of \$49.0M vs \$49.24M Est

Financial news for VIVO dated on 2013-11-06: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin

Financial news for VIVO dated on 2013-11-01: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2013-10-21: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Financial news for VIVO dated on 2013-10-01: Top 4 NASDAQ Stocks In The Diagnostic

Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2013-09-19: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Profit Margin

Financial news for VIVO dated on 2013-09-09: Meridian Bioscience Shares Volatile But Largely Unch Following News FY13 Sales Will Be at Low-End of Prior Range, FY14 Sales Expected \$203-208M vs \$205.6M Est, EPS \$0.98-1.03 vs \$1.01 Est.

Financial news for VIVO dated on 2013-09-03: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin

Financial news for VIVO dated on 2013-08-19: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2013-07-30: Meridian Life Science(r) Successfully Manufactures Influenza Challenge Stock for Immune Targeting Systems

Financial news for VIVO dated on 2013-07-26: Wedbush Upgrades Meridian Bioscience Inc. to Neutral, Raises PT to \$21.00

Financial news for VIVO dated on 2013-07-25: Meridian Bioscience Inc. Reports Q2 EPS of \$0.24 vs \$0.22 Est; Revenue of \$47.10M vs \$46.96M Est

Financial news for VIVO dated on 2013-07-16: UPDATE: Cowen and Company Downgrades Meridian Bioscience on Tough Road Ahead

Financial news for VIVO dated on 2013-07-16: Cowen & Company Downgrades Meridian Bioscience Inc. to Market Perform, Lowers PT to \$21.00

Financial news for VIVO dated on 2013-06-10: UPDATE: Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene Mycoplasma

Financial news for VIVO dated on 2013-04-30: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2013-04-29: Stocks Going Ex Dividend the First Week of May

Financial news for VIVO dated on 2013-04-26: Craig-Hallum Downgrades Meridian Bioscience Inc. to Hold, Lowers PT to \$22.00

Financial news for VIVO dated on 2013-04-25: Meridian Bioscience Inc. Reports Q2 EPS of \$0.24, Inline; Revenue of \$47.30M vs \$49.66M Est

Financial news for VIVO dated on 2013-04-18: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin

Financial news for VIVO dated on 2013-03-20: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue

Financial news for VIVO dated on 2013-02-21: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates For The Next Quarter

Financial news for VIVO dated on 2013-02-06: Meridian Subsidiary Bioline, Launches ISOLATE II

Financial news for VIVO dated on 2013-01-24: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Financial news for VIVO dated on 2013-01-23: Canaccord Genuity Maintains Hold on Meridian Bioscience Inc., Raises PT to \$20.00

Financial news for VIVO dated on 2013-01-23: Meridian Bioscience Inc. Reports Q1 EPS of \$0.20 vs \$0.19 Est; Revenue of \$45.40M vs \$44.34M Est

Financial news for VIVO dated on 2013-01-08: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Profit Margin

Financial news for VIVO dated on 2012-12-20: Top 4 Stocks In The Diagnostic Substances Industry With The Highest Profit Margin

Financial news for VIVO dated on 2012-11-28: UPDATE: Wedbush Securities Downgrades Meridian Bioscience to Underperform, Reiterates \$17 PT

Financial news for VIVO dated on 2012-11-28: UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform, Maintains PT to \$17.0

Financial news for VIVO dated on 2012-11-28: Wedbush Downgrades Meridian Bioscience

Inc.

Financial news for VIVO dated on 2012-11-08: Meridian Bioscience Reports Q4 EPS \$0.21 vs \$0.19 Est; Revenues \$43.7M vs \$42.97M Est

Financial news for VIVO dated on 2012-10-24: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROE

Financial news for VIVO dated on 2012-10-10: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates

Financial news for VIVO dated on 2012-10-02: Cowen Initiates Coverage Meridian Bioscience at Outperform

Financial news for VIVO dated on 2012-09-21: Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Profit Margin

Financial news for VIVO dated on 2012-09-17: Meridian bioscience Gets FDA Clearance for New Molecular Test illumigene Group A Strep

Financial news for VIVO dated on 2012-08-28: Meridian Guides FY 2013 Revenue \$190M-195M; FY EPS \$0.86-0.91

Financial news for VIVO dated on 2012-07-31: Wedbush Securities Upgrades Meridian Bioscience from Underperform to Neutral

Financial news for VIVO dated on 2012-07-27: UPDATE: Canaccord Genuity Downgrades Meridian Bioscience to Hold on FQ3 Report

Financial news for VIVO dated on 2012-07-27: Canaccord Downgrades Meridian Bioscience from Buy to Hold, Lowers PT from \$25 to \$18

Financial news for VIVO dated on 2012-07-11: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Financial news for VIVO dated on 2012-05-14: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Profit Margin

Financial news for VIVO dated on 2012-04-26: Meridian Bioscience Reports Q2 EPS \$0.23 vs \$0.21 Est; Revenues \$47.4M vs \$44.81M Est

Financial news for VIVO dated on 2012-04-12: Meridian Bioscience Awarded New Agreement with Premier Healthcare Alliance for Molecular Diagnostic Tests and Instruments for C

Financial news for VIVO dated on 2012-03-30: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2012-03-21: Financial Breakfast: Morning News Summary for March 21, 2012

Financial news for VIVO dated on 2012-03-21: Bioline Receives Clearance from TGA for the Commercialization in Australia of the New Molecular Test illumigene(r) Group B Streptococcus

Financial news for VIVO dated on 2012-02-27: Meridian Bioscience Receives FDA Clearance for New Legionella Test

Financial news for VIVO dated on 2012-02-27: Top 4 Stocks In The Diagnostic Substances Industry With The Highest Profit Margin

Financial news for VIVO dated on 2012-02-13: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

Financial news for VIVO dated on 2012-01-31: UPDATE: Wedbush Downgrades Meridian Bioscience to Underperform

Financial news for VIVO dated on 2012-01-31: Wedbush Downgrades Meridian Bioscience to Underperform

Financial news for VIVO dated on 2011-12-27: Meridian Bioscience Receives FDA Clearance For ImmunoCard C. difficile GDH Test

Financial news for VIVO dated on 2011-12-12: Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene Group B Streptococcus

Financial news for VIVO dated on 2011-11-29: Meridian Bioscience Files Automatic Mixed Securities Shelf

Financial news for VIVO dated on 2011-11-10: Piper Jaffray Remains Underweight On Meridian Biosciences

Financial news for VIVO dated on 2011-11-10: Meridian Bioscience Reports Q3 EPS \$0.18 vs \$0.19 Est; Revenues \$41.30M vs \$42.11M Est

Financial news for VIVO dated on 2011-11-07: Wedbush Lowers PT on Meridian Bioscience to \$16

Financial news for VIVO dated on 2011-09-20: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Financial news for VIVO dated on 2011-09-13: Piper Jaffray Underweight On Meridian Bioscience

Financial news for VIVO dated on 2011-09-13: Piper Jaffray Initiates Meridian Bioscience At Underweight, \$14 PT

Financial news for VIVO dated on 2011-08-25: UPDATE: Meridian Bioscience Sees FY2012 EPS of \$0.85-0.89 vs \$0.87

Financial news for VIVO dated on 2011-08-25: UPDATE: Meridian Bioscience Sees FY2012 Sales of \$183-192M vs 184.18M

Financial news for VIVO dated on 2011-08-25: Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2012 and Comments on Fiscal 2011 Guidance

Financial news for VIVO dated on 2011-08-09: Meridian Bioscience Launches ImmunoCard C. difficile GDH Assay in Europe

Financial news for VIVO dated on 2011-07-21: Biggest Losers in Pre-Market Trading

Financial news for VIVO dated on 2011-07-20: Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows

Financial news for VIVO dated on 2011-07-17: Stocks to Watch for Monday 7/18/2011: Fresh 52 Week Highs and Lows

Financial news for VIVO dated on 2011-06-10: Meridian Tests Detect Deadly Toxins Produced by E. coli O104 Outbreak Strain

Financial news for VIVO dated on 2011-06-07: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROE

Financial news for VIVO dated on 2011-05-17: Top 4 Small-Cap Stocks In The Diagnostic Substance Industry With The Highest Operating Margin (AXK, BLUD, VIVO, NEOG)

Financial news for VIVO dated on 2011-05-10: Meridian Bioscience Receives FDA Clearance for New Premier C. difficile GDH Assay

Financial news for VIVO dated on 2011-05-10: Market Analysts coverage on 5/10/11- NRG, OLP, RIO, TAL, TRGP, VIVO, VRX, VVC, AAUKY, BHP, BOBE, CEPH, CSCO, CZZ, GPK, MDVN, NGLS, NNA

Financial news for VIVO dated on 2011-04-21: Meridian Bioscience Reports Q2 EPS \$0.20 ex-items vs. \$0.20; Revenues \$41.1M vs. \$41.2M Est. (VIVO)

Financial news for VIVO dated on 2011-04-14: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue (BLUD, NEOG, ABAX, VIVO)

Financial news for VIVO dated on 2011-04-06: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates (DBD, NEOG, VIVO, ABAX)

Financial news for VIVO dated on 2011-03-24: Canaccord Ups VIVO To Buy

Financial news for VIVO dated on 2011-03-02: Meridian Bioscience Receives FDA Clearance For New illumigene C. difficile Pediatric Claim

Financial news for VIVO dated on 2011-01-24: Meridian Misses on Lower Flu Sales - Analyst Blog

Financial news for VIVO dated on 2011-01-24: Meridian Misses on Lower Flu Sales - Analyst Blog

Financial news for VIVO dated on 2011-01-18: Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Profit Margin (TRIB, AXK, BLUD, VIVO)

Financial news for VIVO dated on 2011-01-13: Bearish MACD for VIVO - Tale of the Tape

Financial news for VIVO dated on 2011-01-13: Bearish MACD for VIVO - Tale of the Tape

Financial news for VIVO dated on 2010-11-17: Top 4 Stocks In The Diagnostic Substances Industry With The Highest Profit Margin (TRIB, BLUD, VIVO, QDEL)

Financial news for VIVO dated on 2010-09-17: VCA ANTECH INC (WOOF) - Profit Tracks

Financial news for VIVO dated on 2010-09-16: Zacks Sell List Highlights: Revlon, VCA Antech, Meridian Bioscience and Stillwater Mining Company - Press Releases

Financial news for VIVO dated on 2010-09-14: Meridian Bullish About Fiscal 2011 - Analyst Blog

Financial news for VIVO dated on 2010-09-13: Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2011

Financial news for VIVO dated on 2010-08-04: Top 4 NASDAQ Stocks In The Healthcare Sector With The Highest Dividend Yield (CMED, VIVO, LNCR, ACET)

Financial news for VIVO dated on 2010-07-21: William Blair & Co. Reiterates Market Perform on Meridian Bioscience (VIVO)

Financial news for VIVO dated on 2010-07-20: Meridian Bioscience (VIVO) Sales Falls 11%

Financial news for VIVO dated on 2010-06-14: Jefferies Global Life Sciences Conference Takeaways; Diagnostics

Financial news for VIVO dated on 2010-03-18: William Blair & Company Maintains Meridian Bioscience (VIVO) Market Perform Rating

Financial news for VIVO dated on 2009-11-12: Hilliard Lyons Reiterates Long Term Buy Rating On VIVO